文献速递眼底病与葡萄膜炎眼整形与眼眶

基于美国癌症联合委员会分期(第八版)的432例虹膜黑色素瘤结局分析

Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients.
PubMed 文献 · Ophthalmology · 2018-01-17

该回顾性病例系列纳入432例虹膜黑色素瘤患者,按AJCC第八版分期评估局部复发、全身转移和死亡等结局。多因素分析显示,T2和T4期患者黑色素瘤相关转移风险分别约为T1期的4倍和31倍,死亡风险分别约为8倍和20倍;T3期队列过小无法提供有效信息。

要点

  • 432例虹膜黑色素瘤中T1期324例(75%)、T2期83例(19%)、T4期23例(5%)、T3期仅2例(<1%)。
  • 多因素分析中,T2期和T4期黑色素瘤相关转移风险分别为T1期的4.09倍和30.8倍,死亡风险分别为8.07倍和20.3倍。
  • 继发性青光眼是多因素分析中黑色素瘤相关转移的预测因素(P<0.001;HR 4.51)。

核心结论

  • AJCC第八版分期可对虹膜黑色素瘤提供预后分层。
  • 多因素分析中,T2期和T4期黑色素瘤相关转移风险分别约为T1期的4倍和31倍,死亡风险分别约为8倍和20倍。
  • T3期队列过小,无法提供有效信息。

研究设计与样本

  • 回顾性病例系列,纳入432例虹膜黑色素瘤患者。
  • 治疗方式包括肿瘤切除、敷贴放疗或眼球摘除。
  • 主要结局指标为局部肿瘤复发、黑色素瘤相关全身转移和黑色素瘤相关死亡。

主要发现

  • 432例中AJCC分期为T1期324例(75%)、T2期83例(19%)、T3期2例(<1%)、T4期23例(5%)。
  • 各T分期之间在年龄、种族、性别、眼别或虹膜颜色方面无差异。
  • Kaplan-Meier分析5年和10年结局:视力下降≥3行分别为42%和54%,继发性青光眼分别为29%和33%,局部复发分别为8%和17%,继发性眼球摘除分别为12%和19%,淋巴结转移分别为1%和1%,黑色素瘤相关全身转移分别为5%和10%,黑色素瘤相关死亡分别为3%和4%。
  • 与T1期相比,非眼球摘除眼局部复发的HR:T2期为1.31,T3期因队列过小无法评估(NE),T4期为6.61;转移的HR:T2期为3.41,T3期NE,T4期为25.6;死亡的HR:T2期为7.51,T3期NE,T4期为26.5;眼球摘除的比值比:T2期为1.23,T3期为3.63,T4期为4.72。
  • 多因素分析中黑色素瘤相关转移的预测因素包括继发性青光眼(P<0.001;HR 4.51)、T2期(对比T1期;P=0.01;HR 4.09)和T4期(对比T1期;P<0.001;HR 30.8);黑色素瘤相关死亡的预测因素包括年龄较大(P=0.008;每增加10岁HR 2.16)、T2期(对比T1期;P=0.005;HR 8.07)和T4期(对比T1期;P<0.001;HR 20.3)。

关键数值与推荐

  • AJCC第八版分类中,虹膜黑色素瘤T1期324例(75%)、T2期83例(19%)、T3期2例(<1%)、T4期23例(5%)。
  • 多因素分析中T2期对比T1期黑色素瘤相关转移的HR为4.09(P=0.01),T4期对比T1期的HR为30.8(P<0.001)。
  • 多因素分析中T2期对比T1期黑色素瘤相关死亡的HR为8.07(P=0.005),T4期对比T1期的HR为20.3(P<0.001)。
  • 多因素分析中继发性青光眼预测黑色素瘤相关转移的HR为4.51(P<0.001)。
  • 多因素分析中年龄每增加10岁预测黑色素瘤相关死亡的HR为2.16(P=0.008)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • T3期队列过小,无法提供有效信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The American Joint Committee on Cancer (AJCC) classification was updated to the eighth edition in January 2017, providing staging for iris melanoma. This study evaluated outcomes of iris melanoma per the AJCC classification, eighth edition. DESIGN: Retrospective case series. PARTICIPANTS: Four hundred thirty-two patients with iris melanoma. METHODS: Management including tumor resection, plaque radiotherapy, or enucleation. MAIN OUTCOME MEASURES: Local tumor recurrence, melanoma-related systemic metastasis, and melanoma-related death. RESULTS: Of 432 patients with iris melanoma, AJCC classification was category T1 (n = 324 [75%]), T2 (n = 83 [19%]), T3 (n = 2 [<1%]), and T4 (n = 23 [5%]). There was no difference in age, race, gender, eye, or iris color among T categories. Overall, Kaplan-Meier analysis of outcomes (at 5 and 10 years) revealed visual acuity reduction by 3 lines or more (42% and 54%, respectively), secondary glaucoma (29% and 33%, respectively), local recurrence (8% and 17%, respectively), secondary enucleation (12% and 19%, respectively), lymph node metastasis (1% and 1%, respectively), melanoma-related systemic metastasis (5% and 10%, respectively), and melanoma-related death (3% and 4%, respectively). Compared with T1 category, the hazard ratio (HR) for local recurrence in nonenucleated eyes was 1.31 for T2, not evaluable (NE) for T3 (because of small cohort), and 6.61 for T4; the HR for metastasis was 3.41 for T2, NE for T3 (because of small cohort), and 25.6 for T4; the HR for death was 7.51 for T2, NE for T3 (because of small cohort), and 26.5 for T4; and the odds ratio for enucleation was 1.23 for T2, 3.63 for T3, and 4.72 for T4. Features predictive of melanoma-related metastasis (multivariate analysis) included secondary glaucoma (P < 0.001; HR, 4.51), T2 category (vs. T1; P = 0.01; HR, 4.09), and T4 category (vs. T1; P < 0.001; HR, 30.8). Features predictive of melanoma-related death (multivariate analysis) included older age (P = 0.008; HR, 2.16 per 10-year increase), T2 category (vs. T1; P = 0.005; HR, 8.07), and T4 category (vs. T1; P < 0.001; HR, 20.3). CONCLUSIONS: The AJCC eighth edition classification provides prognostic stratification of iris melanoma. By multivariate analysis, the ratio for melanoma-related metastasis was 4 times greater in category T2 and 31 times greater in T4 compared with T1. The ratio for melanoma-related death was 8 times greater in category T2 and 20 times greater in T4 compared with T1. The cohort size for T3 was too small to provide useful information.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Shields CL, Di Nicola M, Bekerman VP, et al. Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients. Ophthalmology. 2018. PMID: 29342436. doi:10.1016/j.ophtha.2017.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。